PITU is designed to temporarily isolate and transport patients with confirmed or suspected COVID-19 infection.
Arrowhead Medical Center Head of Anesthesiology, Dr. Mark Comunale, worked on developing the unit in 2015 after the outbreak of Ebola. AR Tech joined Dr. Comunale's efforts two years ago.
Currently, PITU is ready for use with FDA Emergency Use Authorization on the frontline in the battle against the novel Coronavirus.
PITU protects medical professionals, patients, and visiting family members against respiratory droplets and infection by using a negative pressure enclosure which surrounds the patient.
Patients can be treated by medical staff, and family members who are properly attired can even visit those patients.
A and R Tarpaulins Inc. is the parent company of AR Tech and AR Industries and provides products and services for medical companies, flight hardware, and ground support to various aerospace companies providing satellite launches.
A and R Tarpaulins also provides architectural products and services for homes and businesses, and industrial products for the transportation industry.
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma